BioNTech SE reported revenues of €1.5 billion for the third quarter of 2025, up from €1.2 billion in the same period last year. For the nine months ended September 30, 2025, revenues reached €2.0 billion, compared to €1.6 billion for the prior year period. The increase was primarily attributed to revenues from the company's collaboration with Bristol Myers Squibb, partially offset by lower sales volumes of COVID-19 vaccines. The company reported a net loss of €28.7 million for the third quarter of 2025, with a basic and diluted loss per share of €0.12. R&D expenses for the quarter were €564.8 million, while year-to-date R&D expenses totaled €1.6 billion. BioNTech strengthened its financial position to €16.7 billion in cash, cash equivalents, and security investments, and received a $1.5 billion payment from its partnership with Bristol Myers Squibb. The company increased its full-year 2025 revenue guidance to €2.6-2.8 billion and lowered expense guidance ranges for R&D, SG&A, and capital expenditures. BioNTech does not expect to report a positive net income for the 2025 financial year.